IP Library Patent Application 12447193
Patent Application
App. No. 12/447,193

METHODS FOR REDUCING PHOSPHATE ABSORPTION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/447,193
Abstract

It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia. The method includes the step of administering orally to the subject an anti-phytic acid (C 6 H 6 [OPO(OH) 2 ] o ) antibody or an anti-phytate antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

Claims (17)

1 . A method of reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia, the method comprising the step of:

administering orally to the subject an anti-phytic acid antibody or an anti-phytate antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

2 . The method of claim 1 , wherein the subject has a kidney disease.

3 . The method of claim 2 , wherein the kidney disease is selected from end stage renal disease, acute renal failure, chronic renal failure, polycystic kidney disease, chronic kidney disease, acute tubular necrosis, an infection that reduces kidney function, and a urinary tract obstruction.

4 . The method of claim 1 , wherein the subject is receiving a vitamin D compound.

5 . The method of claim 1 , wherein the antibody is an IgY antibody.

6 . The method of claim 1 , wherein the antibody is obtained from an avian egg.

7 . The method of claim 1 , wherein the antibody is administered with a phosphate binder.

8 . The method of claim 1 , wherein the subject is a human subject.

9 . The method of claim 1 , further comprising the steps of measuring the serum phosphate concentration after the antibody is administered and comparing the concentration to that before the antibody is administered.

10 . A method of reducing phosphate absorption in a human subject who has a kidney disease, receives a vitamin D compound, and consumes a diet containing phytic acid or phytate wherein the vitamin D compound renders the phytic phosphate in the diet available for absorption, the method comprising the step of:

administering orally to the human subject an anti-phytic acid antibody or an anti-phytate antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

11 . The method of claim 10 , wherein the kidney disease is selected from end stage renal disease, acute renal failure, chronic renal failure, polycystic kidney disease, chronic kidney disease, acute tubular necrosis, an infection that reduces kidney function, and a urinary tract obstruction.

12 . The method of claim 10 , wherein the antibody is an IgY antibody.

13 . The method of claim 10 , wherein the antibody is obtained from an avian egg.

14 . The method of claim 10 , wherein the antibody is administered with a phosphate binder.

15 . The method of claim 10 , further comprising the steps of measuring the serum phosphate concentration after the antibody is administered and comparing the concentration to that before the antibody is administered.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Mar 4, 2013
From: COMERICA BANK, A TEXAS BANKING ASSOCIATION AND AUTHORIZED FOREIGN BANK UNDER THE BANK ACT (CANADA)
To: CYTOCHROMA INC.
Reel/Frame 029914/0404 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2012
From: GENERAL ELECTRIC CAPITAL CORPORATION
To: CYTOCHROMA, INC.; CYTOCHROMA HOLDINGS ULC; PROVENTIV THERAPEUTICS, LLC
Reel/Frame 028881/0338 →
SECURITY AGREEMENT Recorded Sep 28, 2010
From: CYTOCHROMA INC.; PROVENTIV THERAPEUTICS, LLC; CYTOCHROMA HOLDINGS ULC
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 025051/0215 →